Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $48.12M
• Dividend Yield: N/A
• Average Volume (3M): 374.39K
• Price to Earnings (P/E): 2.4
• Beta (1Y): 1.14
• Revenue Growth: -11.11%
• EPS Growth: 79.74%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -2.21
• Shares Outstanding: 11,088,234
• 10 Day Avg. Volume: 987,369
• 30 Day Avg. Volume: 374,388
• PEG Ratio: 0.19
• Price to Book (P/B): 4.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.07
• Enterprise Value/Market Cap: -0.90
• Enterprise Value/Revenue: -0.15
• Enterprise Value/Gross Profit: -0.85
• Enterprise Value/Ebitda: -1.08
• 1Y Price Target: $34.33
• Price Target Upside: 705.87% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 41 Neutral
• Price Target: $4.00 ▼(-6.10%Downside)

The overall stock score is driven by financial performance and valuation concerns. The company struggles with negative earnings and cash flow, impacting its financial stability. Technical indicators point to bearish momentum, compounding the negative outlook. Despite positive corporate events, these do not currently offset the financial and technical challenges.

Positive Factors

Preclinical Data

PBGENE-DMD was found to have increased and durable therapeutic benefit as seen through 3 to 9 months post-treatment compared to diseased mice.

Regulatory Progress

The FDA has granted a Rare Pediatric Disease (RPD) Designation for PBGENE-DMD.

Strategic Opportunities

Precision's multi-exon excision strategy could apply to up to 60% of DMD cases, offering a broader treatment approach than current exon skipping drugs.

Negative Factors

Clinical Data Concerns

Investors' key holdup in the stock has been the lack of meaningful clinical data to validate the ARCUS gene editing technology.

Market Competition

A key concern for investors is the lack of meaningful clinical data to validate the ARCUS gene editing technology and its long-lasting clinical benefits with minimal safety concerns.

Safety Concerns

Future updates at higher doses with 2-3 administrations are expected to have a greater degree of toxicity.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Precision BioSciences generates revenue through the development and commercialization of its genome editing technologies. The company's primary revenue streams include licensing agreements and strategic partnerships with other biotechnology and pharmaceutical companies, which utilize the ARCUS platform for their own therapeutic and agricultural applications. Additionally, Precision BioSciences may earn revenue from research and development collaborations, government grants, and potential milestone payments based on the progress and success of its development programs. The company also has the potential to benefit from future product sales if its therapies receive regulatory approval and are brought to market.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences faces significant financial challenges, particularly in profitability and cash flow. Despite a strong cash position, negative earnings, declining equity, and inconsistent revenue growth are major concerns.

Income Statement

The company shows fluctuating revenue with recent declines, as seen in the TTM (Trailing-Twelve-Months) figures. Gross profit margin is solid, but negative EBIT and net income margins indicate operational and profitability challenges. Revenue growth has been inconsistent with a significant drop in the latest TTM period.

Balance Sheet

The company maintains a strong cash position relative to debt, indicating low leverage. However, stockholders' equity has decreased over time, and the equity ratio reflects a relatively weak capital structure. Debt-to-equity ratio is manageable, but the decline in equity is concerning.

Cash Flow

Free cash flow remains negative, with little improvement over time. Operating cash flow is consistently negative, indicating challenges in core business profitability. The operating cash flow to net income ratio is unfavorable, reflecting cash generation issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.14M	68.70M	48.73M	25.10M	115.53M	24.29M
Gross Profit	51.14M	68.70M	40.47M	16.09M	115.53M	24.29M
EBITDA	-16.57M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
Net Income	-21.99M	7.17M	-61.32M	-122.91M	-30.92M	-109.01M
Balance Sheet
Total Assets	124.41M	136.39M	159.78M	238.17M	211.50M	150.16M
Cash, Cash Equivalents and Short-Term Investments	77.22M	86.31M	116.68M	189.58M	143.66M	89.80M
Total Debt	1.36M	30.05M	31.27M	27.04M	9.11M	10.52M
Total Liabilities	75.07M	80.00M	140.92M	177.74M	120.33M	105.73M
Stockholders Equity	49.34M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow
Free Cash Flow	-58.74M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
Operating Cash Flow	-58.52M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
Investing Cash Flow	-503.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
Financing Cash Flow	21.04M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 4.26 is below the 20-day moving average (MA) of 4.72, below the 50-day MA of 4.95, and below the 200-day MA of 5.98, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 41.74 is Neutral, neither overbought nor oversold. The STOCH value of 23.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	68 Neutral	$390.71M	5.00	-58.97%	―	23.81%	146.45%
Sector *	64 Neutral	€7.32B	20.88	0.61%	1.91%	1.18%	-29.88%
IKNA	41 Neutral	$63.22M	―	-30.49%	―	-100.00%	37.59%
DTIL	41 Neutral	$48.12M	2.40	-50.81%	―	-11.11%	79.74%
ACRV	36 Underperform	$40.45M	―	-62.41%	―	―	10.84%
ACET	27 Underperform	$50.20M	―	-55.83%	―	―	59.75%

Precision BioSciences Corporate Events

Precision BioSciences Holds Annual Stockholder Meeting

On May 28, 2025, Precision BioSciences, Inc. held its annual meeting of stockholders, where 71% of the common stock was represented. The meeting resulted in the election of Kevin J. Buehler and Shari Lisa Piré as Class III directors, and the approval of several proposals, including the ratification of Deloitte & Touche LLP as the independent accounting firm and an annual advisory vote on executive compensation. However, a proposal to amend the Certificate of Incorporation regarding officer exculpation did not pass as it failed to meet the required voting threshold.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Reports Q1 Results and Business Update

On May 15, 2025, Precision BioSciences reported its first quarter financial results and provided a business update, highlighting new clinical data for its ARCUS-based programs. The company announced progress in its ELIMINATE-B trial for PBGENE-HBV, a potential curative treatment for chronic Hepatitis B, which received Fast Track Designation from the FDA. Additionally, Precision is accelerating its PBGENE-DMD program for Duchenne’s Muscular Dystrophy, aiming to file an IND/CTA in 2025, with clinical data expected in 2026. The company plans to pause the development of PBGENE-3243 to focus resources on these programs.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Accelerates PBGENE-DMD Program for DMD

On May 14, 2025, Precision BioSciences announced the acceleration of its PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD), highlighting preclinical evidence at the ASGCT Annual Meeting. The program aims to address the significant unmet need for DMD treatments by restoring the body’s production of functional dystrophin protein, potentially offering a durable intervention for most patients. Precision plans to submit an IND and/or CTA in 2025, with clinical data expected in 2026, while pausing development of PBGENE-3243 to focus on advancing PBGENE-DMD and PBGENE-HBV through Phase 1 clinical results.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.